Aurinia Pharmaceuticals Inc. (FRA:IKAP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 1.73B |
| Revenue (ttm) | 226.55M |
| Net Income (ttm) | 66.34M |
| Shares Out | n/a |
| EPS (ttm) | 0.47 |
| PE Ratio | 26.09 |
| Forward PE | 17.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 5 |
| Open | 12.91 |
| Previous Close | 12.59 |
| Day's Range | 12.91 - 12.91 |
| 52-Week Range | 6.19 - 14.27 |
| Beta | n/a |
| RSI | 47.45 |
| Earnings Date | Feb 26, 2026 |
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was ... [Read more]
News
AUPH Sees Downgrade by Leerink Partners as Price Target is Raised | AUPH Stock News
AUPH Sees Downgrade by Leerink Partners as Price Target is Raised | AUPH Stock News
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
San Diego-based Tang Capital Management increased its position in AUPH by 1.3 million shares in the third quarter. Following the transaction, Tang reported holding more than 11.3 million AUPH shares v...
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Investors need to pay close attention to AUPH stock based on the movements in the options market lately.
First Week of AUPH July 2026 Options Trading
Investors in Aurinia Pharmaceuticals Inc (Symbol: AUPH) saw new options begin trading this week, for the July 2026 expiration. One of the key inputs that goes into the price an option buyer is willing...
FDA Appointment Boosts Aurinia Pharma (AUPH) and Biotech Stocks
FDA Appointment Boosts Aurinia Pharma (AUPH) and Biotech Stocks
Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates?
Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Jefferies Upgrades Aurinia Pharmaceuticals (AUPH) to Buy, Raises Price Target | AUPH Stock News
Jefferies Upgrades Aurinia Pharmaceuticals (AUPH) to Buy, Raises Price Target | AUPH Stock News
AUPH: RBC Capital Downgrades Aurinia Pharmaceuticals, Raises Price Target | AUPH Stock News
AUPH: RBC Capital Downgrades Aurinia Pharmaceuticals, Raises Price Target | AUPH Stock News
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT Insight
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT Insight
Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call Highlights: Strong Lupkynis Sales and ...
Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call Highlights: Strong Lupkynis Sales and Raised Guidance Amid Regulatory Challenges
Aurinia Pharmaceuticals Stock Gains 7% After Q3 Revenue Beat & Raised Guidance
(RTTNews) - Aurinia Pharmaceuticals Inc. (AUPH) climbed 7.52% to $14.16, up $0.99, after it reported third-quarter 2025 results showing total revenue of $73.5 million - up 8 percent year-over-year and...
Aurinia Pharmaceuticals (AUPH) Surges After Q3 Earnings Beat and Revenue Boost
Aurinia Pharmaceuticals (AUPH) Surges After Q3 Earnings Beat and Revenue Boost
Aurinia Pharmaceuticals (AUPH) Boosts 2025 Revenue Guidance Amid Strong LUPKYNIS Sales
Aurinia Pharmaceuticals (AUPH) Boosts 2025 Revenue Guidance Amid Strong LUPKYNIS Sales
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Aruinia discloses FDA information request on Lupkynis amid top regulator’s exit
Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request on its lead drug Lupkynis. Read more here.
Aurinia Pharmaceuticals Inc. 2025 Q3 - Results - Earnings Call Presentation
2025-11-04. The following slide deck was published by Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings: EPS of $0. ...
Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings: EPS of $0.23 Beats Estimates, Revenue Surges to $73.5 Million
Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of +43.75% and +7.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharma Q3 Earnings Soar; Stock Up In Pre-market; Lifts Annual Outlook
(RTTNews) - Aurinia Pharmaceuticals Inc. (AUPH), a pharmaceutical company, Tuesday reported higher earnings and revenue for the third quarter compared to the same period last year.
Aurinia (AUPH) Raises 2025 Revenue and Sales Projections
Aurinia (AUPH) Raises 2025 Revenue and Sales Projections
Aurinia (AUPH) Surpasses Revenue Expectations in Q3
Aurinia (AUPH) Surpasses Revenue Expectations in Q3
Aurinia Pharma GAAP EPS of $0.23 beats by $0.07, revenue of $73.47M beats by $5.77M
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress. Financial Resu...
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided ...
Wall Street Breakfast Podcast: FDA Executive Controversy
Aurinia Pharmaceuticals (AUPH) files a federal lawsuit against FDA's George Tidmarsh for alleged false statements about its lupus nephritis drug. Baidu's (BIDU) Apollo Go robotaxi service matches Waym...